PMID- 38075033
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231211
IS  - 2391-5463 (Print)
IS  - 2391-5463 (Electronic)
VI  - 18
IP  - 1
DP  - 2023
TI  - Serum VEGF, high-sensitivity CRP, and cystatin-C assist in the diagnosis of type 
      2 diabetic retinopathy complicated with hyperuricemia.
PG  - 20230857
LID - 10.1515/med-2023-0857 [doi]
LID - 20230857
AB  - Elevated serum uric acid (UA) level is related to type 2 diabetic retinopathy 
      (DR). Vascular endothelial growth factor (VEGF), high-sensitivity C-reactive 
      protein (hs-CRP), and cystatin C (Cys-C) have involvement in type 2 DR 
      complicated with hyperuricemia (HUA) (HUDR), and we explored their clinical 
      values in HUDR. Type 2 DR patients were allocated into HUDR/DR groups, with type 
      2 diabetes mellitus (T2DM) patients as the control group. Serum VEGF and 
      inflammation markers hs-CRP, and Cys-C levels were assessed by ELISA and 
      immunoturbidimetry. The correlations between serum UA level and VEGF/hs-CRP/Cys-C 
      were analyzed by Pearson tests, diagnostic values of VEGF/hs-CRP/Cys-C were 
      analyzed by receiver operating characteristic curves, and the independent risk 
      factors in HUDR were analyzed by logistic multivariate regression. Serum 
      VEGF/hs-CRP/Cys-C level differences among the T2DM/DR/HUDR groups were 
      statistically significant, with the levels in HUDR > DR > T2DM. Serum UA level in 
      HUDR patients was positively correlated with serum VEGF/hs-CRP/Cys-C. Serum 
      VEGF/hs-CRP/Cys-C assisted in HUDR diagnosis, with their combination showing the 
      greatest diagnostic value. UA/FPG/HbA1C/VEGF/hs-CRP/Cys-C were independent risk 
      factors for HUDR. The incidence of proliferative DR was increased in HUDR 
      patients. Collectively, serum VEGF, hs-CRP, and Cys-C levels in HUDR patients 
      were increased, and HUA might promote DR progression.
CI  - (c) 2023 the author(s), published by De Gruyter.
FAU - Wei, Jing
AU  - Wei J
AD  - No.1 Department of Endocrinology, Cangzhou Central Hospital, Cangzhou City, Hebei 
      Province, 061000, China.
FAU - Zhang, Jincheng
AU  - Zhang J
AD  - No.1 Department of Endocrinology, Cangzhou Central Hospital, 16 West Xinhua Road, 
      Cangzhou City, Hebei Province, 061000, China.
FAU - Shi, Yanan
AU  - Shi Y
AD  - No.1 Department of Endocrinology, Cangzhou Central Hospital, Cangzhou City, Hebei 
      Province, 061000, China.
FAU - Zhang, Huiqin
AU  - Zhang H
AD  - No.1 Department of Ophthalmology, Cangzhou Central Hospital, Cangzhou City, Hebei 
      Province, 061000, China.
FAU - Wu, Yan
AU  - Wu Y
AD  - No.1 Department of Endocrinology, Cangzhou Central Hospital, Cangzhou City, Hebei 
      Province, 061000, China.
LA  - eng
PT  - Journal Article
DEP - 20231207
PL  - Poland
TA  - Open Med (Wars)
JT  - Open medicine (Warsaw, Poland)
JID - 101672167
PMC - PMC10710213
OTO - NOTNLM
OT  - Pearson test
OT  - cystatin C
OT  - high-sensitivity C-reactive protein
OT  - hyperuricemia
OT  - inflammation
OT  - logistic multiple factor regression analysis
OT  - receiver operating characteristic curve
OT  - retinopathy
OT  - type 2 diabetes mellitus
OT  - vascular endothelial growth factor
COIS- Conflict of interest: All authors declare that there is no conflict of interests 
      in this study.
EDAT- 2023/12/11 06:45
MHDA- 2023/12/11 06:46
PMCR- 2023/12/07
CRDT- 2023/12/11 05:52
PHST- 2023/04/28 00:00 [received]
PHST- 2023/10/27 00:00 [revised]
PHST- 2023/10/29 00:00 [accepted]
PHST- 2023/12/11 06:46 [medline]
PHST- 2023/12/11 06:45 [pubmed]
PHST- 2023/12/11 05:52 [entrez]
PHST- 2023/12/07 00:00 [pmc-release]
AID - med-2023-0857 [pii]
AID - 10.1515/med-2023-0857 [doi]
PST - epublish
SO  - Open Med (Wars). 2023 Dec 7;18(1):20230857. doi: 10.1515/med-2023-0857. 
      eCollection 2023.